NIAID Banner Logo Image


1. 47870 HIV-LS-331; PUBMED-HIV-9/19/2005

Computational Studies and Drug Design for HIV-1 Reverse Transcriptase Inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-Khellactone (DCK) Analogs

Chen, HF, Fan, BT, Zhao, CY, Xie, L, Zhao, CH, Zhou, T, Lee, KH, and Allaway, G

J Comput Aided Mol Des 2005. 19(4): 243-58


2. 47871 HIV-LS-331; PUBMED-HIV-9/19/2005

Quantitative Structure-activity Relationship Analysis of Pyridinone HIV-1 Reverse Transcriptase Inhibitors using the k Nearest Neighbor Method and QSAR-based Database Mining

Medina-Franco, JL, Golbraikh, A, Oloff, S, Castillo, R, and Tropsha, A

J Comput Aided Mol Des 2005. 19(4): 229-42


3. 47872 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Preparation of PNA-neamine conjugates as antiviral agents

Decout, Jean-Luc, Pandey, Virendra N, and Riguet, Emmanuel

PATENT: WO 2005060573 ISSUE DATE: 20050707

APPLICATION: 2004 PP: 67 pp.

ASSIGNEE: (University of Medicine and Dentistry of New Jersey, USA and Universite Joseph Fourier)

4. 47873 HIV-LS-331; PUBMED-HIV-9/19/2005

Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Deng, BL, Hartman, TL, Buckheit, RW Jr, Pannecouque, C, De, Clercq E, Fanwick, PE, and Cushman, M

J Med Chem 2005. 48(19): 6140-6155


5. 47874 HIV-LS-331; PUBMED-HIV-9/19/2005

Naturally derived anti-HIV agents

Asres, K, Seyoum, A, Veeresham, C, Bucar, F, and Gibbons, S

Phytother Res 2005. 19(7): 557-581


6. 47875 HIV-LS-331; PUBMED-HIV-9/19/2005

Targeting HIV protease: From peptidomimetics to non-peptide inhibitors

Gago, F

IDrugs 1999. 2(4): 309-20


7. 47876 HIV-LS-331; PUBMED-HIV-9/19/2005

Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density

Willey, S, Peters, PJ, Sullivan, WM, Dorr, P, Perros, M, and Clapham, PR

Antiviral Res 2005.


8. 47877 HIV-LS-331; PUBMED-HIV-9/19/2005

A novel heme-containing protein with anti-HIV-1 activity from skin secretions of Bufo andrewsi

Zhao, Y, Jin, Y, Wang, JH, Wang, RR, Yang, LM, Lee, WH, Zheng, YT, and Zhang, Y

Toxicon 2005.


9. 47878 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors

Westby, Mike, Nakayama, Grace R, Butler, Scott L, and Blair, Wade S

Antiviral Research 2005. 67(3): 121-140

10. 47879 HIV-LS-331; SCIFINDER-HIV-9/15/2005

New and improved 5,10-dihydrobenzo[b][1,8]naphthyridine-N-oxides as the next generation NNRTI's with better activity profiles against clinically relevant HIV-1 mutants

Srivastava, Anurag S, Tarby, Christine M, Johnson, Barry M, Rajagopal, Bhakthavatchalam, Curry, Matthew, Lin, Qiyan, Wang, Haisheng, Cocuzza, Anthony J, Bilder, Donna M, McHugh, Robert J, Patel, Mona, Bacheler, Lee T, Diamond, Sharon, Jeffrey, Susan, Klabe, Ronald M, Cordova, Beverly C, Garber, Sena, Logue, Kelly, Erickson-Viitanen, Susan, Trainor, George L, and Rodgers, James D

Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 2005.: MEDI-181

11. 47880 HIV-LS-331; PUBMED-HIV-9/19/2005

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection

Bianchi, E, Finotto, M, Ingallinella, P, Hrin, R, Carella, AV, Hou, XS, Schleif, WA, Miller, MD, Geleziunas, R, and Pessi, A

Proc Natl Acad Sci U S A 2005. 102(36): 12903-8


12. 47881 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Inhibiting replication of a retrovirus, such as human immunodeficiency virus (HIV), through modulation of HIV Vif- or Vpu-mediated ubiquitylation of host cell proteins, such as CEM15 or CD4

Payan, Donald G and Jenkins, Yonchu

PATENT: WO 2005047476 ISSUE DATE: 20050526

APPLICATION: 2004 PP: 109 pp.

ASSIGNEE: (Rigel Pharmaceuticals, Inc. USA

13. 47882 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Aminopyrimidinimino isatin analogues: Design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum anti-microbial properties

Sriram, Dharmarajan, Bal, Tanushree Ratan, and Yogeeswari, Perumal

Medicinal Chemistry 2005. 1(3): 277-285

14. 47883 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency

Lori, Franco, Pollard, RB, Whitman, L, Bakare, N, Blick, G, Shalit, P, Foli, A, Peterson, D, Tennenberg, A, Schrader, S, Rashbaum, B, Farthing, C, Herman, D, Norris, D, Greiger, P, Frank, I, Groff, A, Lova, L, Asmuth, D, and Lisziewicz, J

AIDS Research and Human Retroviruses 2005. 21(4): 263-272

15. 47884 HIV-LS-331; PUBMED-HIV-9/19/2005

Long-Term Inhibition of HIV-1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TAR Decoy

Li, MJ, Kim, J, Li, S, Zaia, J, Yee, JK, Anderson, J, Akkina, R, and Rossi, JJ

Mol Ther 2005.


16. 47885 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Syntheses and anti-viral properties of N-6 substituted derivatives of L-like 4'-deoxy-5'-noraristeromycin and oxyamino and hydroxylamino carbanucleosides

Serbessa, Tesfaye, Roy, Atanu, Yang, Minmin, and Schneller, Stewart W

229th ACS National Meeting 2005. 229: MEDI-341

17. 47886 HIV-LS-331; SCIFINDER-HIV-9/15/2005

Preparation of pyrido[1,2-a]pyrazine-1,8-dione derivatives as HIV integrase inhibitors

Miyazaki, Susumu, Katoh, Susumu, Adachi, Kaoru, Isoshima, Hirotaka, Kobayashi, Satoru, Matsuzaki, Yuji, Watanabe, Wataru, Yamataka, Kazunobu, Kiyonari, Shinichi, and Wamaki, Shuichi

PATENT: WO 2005016927 ISSUE DATE: 20050224

APPLICATION: 2004 PP: 355 pp.

ASSIGNEE: (Japan Tobacco Inc., Japan

18. 47887 HIV-LS-331; WOS-HIV-9/11/2005

Darunavir - Anti-HIV agent HIV protease inhibitor

Sorbera, LA, Castaner, J, and Bayes, M

DRUGS OF THE FUTURE 2005. 30(5): 441-449, 9


19. 47888 HIV-LS-331; WOS-HIV-9/11/2005

Etravirine - Anti-HIV agent reverse transcriptase inhibitor

Davies, SL, Castaner, J, Silvestre, JS, and Bayes, M

DRUGS OF THE FUTURE 2005. 30(5): 462-468, 7


20. 47889 HIV-LS-331; WOS-HIV-9/11/2005

Maraviroc - Anti-HIV agent viral entry inhibitor chemokine CCR5 antagonist

Ginesta, JB, Castaner, J, Bozzo, J, and Bayes, M

DRUGS OF THE FUTURE 2005. 30(5): 469-477, 9


21. 47890 HIV-LS-331; WOS-HIV-9/18/2005

L-carnitine, immunomodulation, and human immunodeficiency virus (HIV)-related disorders

Alesci, S, Gerschenson, M, and Ilias, L

MONATSHEFTE FUR CHEMIE 2005. 136(8): 1493-1500, 8


22. 47891 HIV-LS-331; WOS-HIV-9/18/2005

The synthetic peptide derived from the NH2-terminal extracellular region of an orphan G protein-coupled receptor, GPR1, preferentially inhibits infection of X4 HIV-1

Jinno-Oue, A, Shimizu, N, Soda, Y, Tanaka, A, Ohtsuki, T, Kurosaki, D, Suzuki, Y, and Hoshino, H

JOURNAL OF BIOLOGICAL CHEMISTRY 2005. 280(35): 30924-30934, 11


23. 47892 HIV-LS-331; WOS-HIV-9/18/2005

New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: Synthesis and biological activity

Normand-Bayle, M, Benard, C, Zouhiri, F, Mouscadet, JF, Leh, H, Thomas, CM, Mbemba, G, Desmaele, D, and d'Angelo, J



24. 47893 HIV-LS-331; WOS-HIV-9/18/2005

Effect of change in nucleoside structure on the activation and antiviral activity of phosphoramidate derivatives

Venkatachalam, TK, Samuel, P, Qazi, S, and Uckun, FM

BIOORGANIC & MEDICINAL CHEMISTRY 2005. 13(18): 5408-5423, 16


If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: September 2023